JPMorgan lowered the firm’s price target on Genmab (GMAB) to DKK 1,500 from DKK 1,700 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab reports ‘encouraging anti-tumor activity’ for Rina-S in Phase 1/2 trial
- Genmab Continues Share Buy-back Program Amid Strategic Financial Management
- Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital
- Genmab Executes Share Buy-back Transactions in May 2025
- Genmab’s Promising Rina-S Developments Drive Buy Rating Amid Strong Initial Study Results